NCT07368023Not yet recruiting
A Retrospective Study of Safety and Efficacy of Locoregional Therapies Combined With Anti-VEGF/TKIs and Immune Checkpoint Inhibitors for All Comers of Intention-to-treat Patients With Unresectable Hepatocellular Carcinoma
Source: ClinicalTrials.gov · Last updated 26 Jan 2026
Brief summary (registry, in English)
This is a single-center, retrospective cohort study aiming to evaluate the safety and efficacy of a combined conversion therapy strategy for patients with initially unresectable hepatocellular carcinoma (HCC).The primary objective is to assess the outcomes of intention-to-treat (ITT) patients who received multidisciplinary conversion therapy. This therapy combines locoregional treatments (LRT, such as TACE or radiotherapy) with systemic therapy (anti-VEGF/tyrosine kinase inhibitors and immune checkpoint inhibitors) with the goal of down-staging tumors to allow for subsequent curative resection. The study plans to enroll 300 subjects. The exposure group will include approximately 100 patients with initially unresectable HCC who received the combined conversion therapy between January 2018 and December 2024. A control group of about 200 patients with initially resectable HCC who underwent direct radical surgery during the same period will be used for comparison. Data will be collected retrospectively from hospital electronic medical records and the HCC clinical database, with follow-up until December 2025.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 300 (estimated)
- First submitted
- 16 Dec 2025
- Start date
- 25 Jan 2026
- Primary completion date
- 31 Jan 2026
- Lead sponsor
- Ningbo Medical Center Lihuili Hospital
- NCT number
- NCT07368023
What you commit to
- Study type: Observational
- Planned participants: 300
- From 25 Jan 2026 to the primary completion date, 31 Jan 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- Presence of extrahepatic metastasis.
- Presence of Cheng's type IV portal vein tumor thrombus (PVTT).
- Presence of Cheng's type II or III inferior vena cava tumor thrombus (IVCTT).
Who the study is looking for
- Aged 16 years or older.
- Clinical and/or pathological diagnosis of hepatocellular carcinoma (HCC). China Liver Cancer (CNLC) stage I, II, or IIIA.
- Assessed by a multidisciplinary team (MDT) as having initially unresectable HCC.
Age in the registry: 16 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Ningbo Medical Centre Lihuili Hospital Coordinator of this site? Confirm its status | Ningbo | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.